Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492021 | 0.98 | TSHR (0.42) | TSHRFAAHTRPV1LMNATHRB | |
| SCHEMBL4505354 | 0.98 | TSHR (0.42) | TSHRFAAHTRPV1LMNATHRB | |
| SCHEMBL4482866 | 0.98 | TSHR (0.42) | TSHRFAAHTRPV1LMNATHRB | |
| SCHEMBL4492282 | 0.98 | TSHR (0.42) | TSHRFAAHTRPV1LMNATHRB | |
| SCHEMBL3836866 | 0.98 | TSHR (0.42) | TSHRFAAHTRPV1LMNATHRB | |
| SCHEMBL4486439 | 0.98 | TSHR (0.42) | TSHRFAAHTRPV1LMNATHRB | |
| SCHEMBL129840 | 0.92 | — | — | |
| SCHEMBL4492268 | 0.85 | HTT (0.41) | TSHRTHRB | |
| SCHEMBL7627443 | 0.81 | TSHR (0.36) | TSHRFAAHTRPV1OPRM1ALDH1A1 | |
| SCHEMBL12988927 | 0.81 | MEN1 (0.37) | TSHRLMNATHRBALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-10 | — | — | US | claimed |
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | claimed |
| CN-110229171-B | Oxazinoquinazoline and oxazinoquinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-03-12 | — | — | CN | claimed |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2021-02-11 | — | — | US | claimed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | claimed |
| CN-111718332-A | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2020-09-29 | — | — | CN | claimed |
| WO-2020187292-A1 | 2-SUBSTITUTED PYRAZOLEAMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION AND USE THEREOF | 北京赛特明强医药科技有限公司 | 2020-09-24 | — | — | WO | claimed |
| WO-2019170088-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | claimed |
| CN-118076691-A | Polyethylene composition and biaxially stretched film comprising the same | 株式会社LG化学 | 2024-05-24 | — | — | CN | disclosed |
| CN-116057083-B | Polyethylene and preparation method thereof | 株式会社LG化学 | 2024-05-07 | — | — | CN | disclosed |
| CN-114269796-B | Polyethylene and chlorinated polyethylene thereof | 株式会社LG化学 | 2024-03-26 | — | — | CN | disclosed |
| CN-113316583-B | Transition metal compound, catalyst composition, and method for preparing polypropylene using same | 株式会社LG化学 | 2024-03-19 | — | — | CN | disclosed |
| CN-114746455-B | Polyolefin | 株式会社LG化学 | 2024-02-13 | — | — | CN | disclosed |
| CN-117510688-A | Polyethylene having high pressure resistance and crosslinked polyethylene pipe comprising the same | 株式会社LG化学 | 2024-02-06 | — | — | CN | disclosed |
| US-6274654-B1 | 1,3-Disubstituted 6-aminouracils for stabilizing halogenated polymers | WITCO VINYL ADDITIVES GMBH (DE) | 2001-08-14 | — | — | US | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0967245-A1 | 1,3 substituted 6-aminouraciles to stabilize halogenated polymers | Witco Vinyl Additives GmbH (DE) | 1999-12-29 | — | — | EP | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
| EP-0266890-A1 | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
| US-4278773-A | N-HYDROXYETHYLAMIDE, ETHYLENE OXIDE FATTY ALCOHOL ADDUCT | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | WNK1, WNK2, WNK3 | TSHR 4235/4885FAAH 2485/4885TRPV1 2591/4885 |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | WNK1, WNK2, WNK3 | TSHR 4235/4885FAAH 2485/4885TRPV1 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.